Strive (ASST) released third quarter 2026 results that reshaped its recent financial story, reporting US$2.7 million in revenue alongside US$509.03 million in net income from continuing operations.
Strive (ASST) Faces A Valuation Test After Q3 Earnings And Bitcoin Buying
Strive (ASST) released third quarter 2026 results that reshaped its recent financial story, reporting US$2.7 million in revenue alongside US$509.03 million in net income from continuing operations.
Yahoo Finance
Publisher
Nov 18, 2026 at 2:15 AM UTC · 3 分で読める

Entities
bitcoin
Market Impact
BTC-0.34%$64,216
Last Updated
1分前
Strive's recent earnings announcement, impairment on medical device intangibles, and aggressive weekly Bitcoin purchases have landed against a choppy tape, with the share price down 16.1% over the past week and 24.9% over the past month, yet still showing a 22.8% 90 day share price return and a 3 year total shareholder return that has fallen 44.9%. This pattern points to short term momentum fading after a sharp rebound while longer term holders remain deeply under water.
Pressure test Strive's wild mix of Bitcoin exposure and medical device earnings against a curated set of 21 cryptocurrency and blockchain stocks that lean into the same digital asset theme.
Strive trades at a steep discount to analyst targets after a sharp pullback. Yet the mix of medical device impairments and heavy Bitcoin buying raises a simple question: Is this caution mispricing, or basic risk management by the market?
Preferred Price-to-Book of 1.6x: Is it justified?
Strive closed at $18.09 with the market valuing it at a price-to-book ratio of 1.6x, a level that screens as inexpensive when stacked against both peers and the broader US Medical Equipment group.
Market Context
Bitcoin
BTC
$64,208
-0.36% (24H)
Market Cap
$1.29T
24H Volume
$21.7B
24H High
$65,379
Article Intelligence
Key Entities
Topics
Related Coverage
Sponsored
AdNewsLayer Premium
Unlock deeper intelligence.
Ad-free reading, exclusive research, and real-time onchain insights.
Go Premium
